AxoGen (AXGN) shares soared 8.2% in the last trading session to close at $14.71. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.2% gain over the past four weeks.Axogen scored a strong price increase driven by bullish market sentiment surrounding Fed minutes released on Wednesday. For investors' note Fed made an aggressive 50-bps rate cut on Sept.18 which is expected to boost the investment and research scenario within the MedT ...

September has always been the worst month for the stock market. In early September, stocks gyrated as investors were concerned about a cooling U.S. economy. However, things have begun to improve following the Federal Reserve’s half-point interest rate cut that restored faith in economic strength. According to the Dow Jones Market Data, the S&P 500, the Dow and the Nasdaq have gained more than 1% this month and are about to crush their dismal September run for the first time in five years. And since stocks a ...

ALACHUA, Fla. and TAMPA, Fla., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that it has completed the rolling submission process for its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®. “I am proud of the significant progress our team has made towards the regulatory transition of Avance from a tissue to a biologic,” s ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

AxoGen (AXGN) closed the last trading session at $12.35, gaining 32.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $15.50 indicates a 25.5% upside potential.The average comprises six short-term price targets ranging from a low of $12 to a high of $20, with a standard deviation of $2.74. While the lowest estimate indicates a decline of 2.8% from the current price level, the most ...

Have you been paying attention to shares of AxoGen (AXGN) ? Shares have been on the move with the stock up 28.6% over the past month. The stock hit a new 52-week high of $11.76 in the previous session. AxoGen has gained 71.7% since the start of the year compared to the 9.5% move for the Zacks Medical sector and the 7.6% return for the Zacks Medical - Instruments industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings cons ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to______________ Commission file number: 001-36046 Axogen, Inc. (Exa ...

AxoGen, Inc. (NASDAQ:AXGN) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Harold Tamayo - Vice President-Finance and Investor Relations Karen Zaderej - Chairman, Chief Executive Officer and President Nir Naor - Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Sarcone - Jefferies Catlin Cronin - Canaccord Genuity Jayson Bedford - Raymond James Dave Turkaly - Citizens JMP Operator Greetings, and welcome to the AxoGen, Inc. Reports ...

AxoGen (AXGN) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 200%. A quarter ago, it was expected that this regenerative medicine company would post a loss of $0.10 per share when it actually produced a loss of $0.06, delivering a surprise of 40%.Over the last four quarters, th ...

Axogen, Inc Reports Second Quarter 2024 Financial Results ALACHUA and TAMPA, FL – August 8, 2024 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended June 30, 2024. Second Quarter Financial Results • Second quarter revenue was $47.9 million, a 25.6% increase compared to the second quarter of 2023. • In the second quarter of 2024, our gross m ...